RCUS Stock Overview
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Arcus Biosciences Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$25.31|
|52 Week High||US$49.10|
|52 Week Low||US$16.74|
|1 Month Change||31.89%|
|3 Month Change||-31.60%|
|1 Year Change||-12.84%|
|3 Year Change||218.77%|
|5 Year Change||n/a|
|Change since IPO||48.88%|
Recent News & Updates
Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers
One thing we could say about the analysts on Arcus Biosciences, Inc. ( NYSE:RCUS ) - they aren't optimistic, having...
|RCUS||US Biotechs||US Market|
Return vs Industry: RCUS exceeded the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: RCUS exceeded the US Market which returned -18.4% over the past year.
|RCUS Average Weekly Movement||14.2%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: RCUS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: RCUS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease.
Arcus Biosciences Fundamentals Summary
|RCUS fundamental statistics|
Is RCUS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RCUS income statement (TTM)|
|Cost of Revenue||US$258.68m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.80|
|Net Profit Margin||14.67%|
How did RCUS perform over the long term?See historical performance and comparison
Is RCUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RCUS?
Other financial metrics that can be useful for relative valuation.
|What is RCUS's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does RCUS's PE Ratio compare to its peers?
|RCUS PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
DVAX Dynavax Technologies
VSBC VitaSpring Biomedical
RCUS Arcus Biosciences
Price-To-Earnings vs Peers: RCUS is good value based on its Price-To-Earnings Ratio (31.6x) compared to the peer average (603.6x).
Price to Earnings Ratio vs Industry
How does RCUS's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Earnings vs Industry: RCUS is expensive based on its Price-To-Earnings Ratio (31.6x) compared to the US Biotechs industry average (15.4x)
Price to Earnings Ratio vs Fair Ratio
What is RCUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||31.6x|
|Fair PE Ratio||40x|
Price-To-Earnings vs Fair Ratio: RCUS is good value based on its Price-To-Earnings Ratio (31.6x) compared to the estimated Fair Price-To-Earnings Ratio (40x).
Share Price vs Fair Value
What is the Fair Price of RCUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RCUS ($25.31) is trading below our estimate of fair value ($325.76)
Significantly Below Fair Value: RCUS is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: RCUS is good value based on its PEG Ratio (0.7x)
Discover undervalued companies
How is Arcus Biosciences forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RCUS's forecast earnings growth (47.1% per year) is above the savings rate (1.9%).
Earnings vs Market: RCUS's earnings (47.1% per year) are forecast to grow faster than the US market (13.9% per year).
High Growth Earnings: RCUS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RCUS's revenue (47.8% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: RCUS's revenue (47.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RCUS is forecast to be unprofitable in 3 years.
Discover growth companies
How has Arcus Biosciences performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RCUS has high quality earnings.
Growing Profit Margin: RCUS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: RCUS has become profitable over the past 5 years, growing earnings by -11.2% per year.
Accelerating Growth: RCUS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: RCUS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: RCUS's Return on Equity (7.2%) is considered low.
Discover strong past performing companies
How is Arcus Biosciences's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: RCUS's short term assets ($1.3B) exceed its short term liabilities ($161.3M).
Long Term Liabilities: RCUS's short term assets ($1.3B) exceed its long term liabilities ($585.6M).
Debt to Equity History and Analysis
Debt Level: RCUS is debt free.
Reducing Debt: RCUS has not had any debt for past 5 years.
Debt Coverage: RCUS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RCUS has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Arcus Biosciences's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RCUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RCUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RCUS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RCUS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RCUS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Terry Rosen (61 yo)
Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...
CEO Compensation Analysis
Compensation vs Market: Terry's total compensation ($USD9.48M) is above average for companies of similar size in the US market ($USD5.46M).
Compensation vs Earnings: Terry's compensation has been consistent with company performance over the past year.
Experienced Management: RCUS's management team is considered experienced (3.8 years average tenure).
Experienced Board: RCUS's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RCUS insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Arcus Biosciences, Inc.'s employee growth, exchange listings and data sources
- Name: Arcus Biosciences, Inc.
- Ticker: RCUS
- Exchange: NYSE
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.815b
- Shares outstanding: 71.72m
- Website: https://www.arcusbio.com
Number of Employees
- Arcus Biosciences, Inc.
- 3928 Point Eden Way
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.